Outlook Therapeutics, Inc. - Common Stock (OTLK)
Healthcare › Biological Products, (No Diagnostic Substances)
Price History
Feb 9, 2026 — Apr 2, 2026Investment Snapshot
- P/E of 0.4 — trading at a low earnings multiple
- Piotroski F-Score 1/9 — signs of financial weakness
- Loss-making — negative ROE of -1,153.9%
Outlook Therapeutics, Inc. - Common Stock (OTLK) is a Healthcare company operating in Biological Products, (No Diagnostic Substances), listed on the NASDAQ , with a market capitalisation of $17 million . Key value metrics: P/E ratio 0.4, Piotroski F-Score 1 out of 9 .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Outlook Therapeutics, Inc. - Common Stock — Fundamental Analysis Summary
Outlook Therapeutics, Inc. - Common Stock (OTLK) trades at a trailing P/E of 0.4x — 99% below the Healthcare sector average of 25.3x.
On financial health, OTLK shows a weak Piotroski F-Score of 1/9, a signal of deteriorating financial health, and negative return on equity of -1,153.9% (sector average: -19.8%).
StockPik's composite Value Score for OTLK is 25/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
OTLK reports a thin gross margin of 4.0% (sector average: 33.5%) and a negative operating margin of -4,473.3%.
OTLK shows earnings growing at 17%.